Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease

Proteomics - Clinical Applications

Volumn 2, Issue 10-11, 2008, Pages 1484-1497

  Caudle, W Michael ^a   Pan, Sheng ^a   Shi, Min ^a   Quinn, Thomas ^a   Hoekstra, Jake ^a   Beyer, Richard P ^b   Montine, Thomas J ^a   Zhang, Jing ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer disease; Biomarkers; Cerebrospinal fluid; Human brain proteome; Laser dissection microscopy

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN CORTEX; BRAIN FUNCTION; DEGENERATIVE DISEASE; DISEASE SEVERITY; ELECTROPHORESIS; GENETIC ANALYSIS; HUMAN; ION PAIR CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MESENCEPHALON; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PARKINSONISM DEMENTIA COMPLEX; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; UBIQUITINATION;

EID: 67449118593     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800043     Document Type: Review

References (121)

1. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
2. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F. et al., Quantitative analysis of complex protein mixtures using isotopecoded affinity tags. Nat. Biotechnol. 1999, 17, 994-999.
3. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
4. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
5. Yao, X., Freas, A., Ramirez, J., Demirev, P. A., Fenselau, C., Proteolytic 18O labeling for comparative proteomics: Model studies with two serotypes of adenovirus. Anal. Chem. 2001, 73, 2836-2842.
6. Finney, G. L., Blackler, A. R., Hoopmann, M. R., Canterbury, J. D. et al., Label-free comparative analysis of proteomics mixtures using chromatographic alignment of high-resolution muLC-MS data. Anal. Chem. 2008, 80, 961-971.
7. Cutillas, P. R., Vanhaesebroeck, B., Quantitative profile of five murine core proteomes using label-free functional proteomics. Mol. Cell. Proteomics 2007, 6, 1560-1573.
8. Park, Y. M., Kim, J. Y., Kwon, K. H., Lee, S. K. et al., Profiling human brain proteome by multi-dimensional separations coupled with MS. Proteomics 2006, 6, 4978-4986.
9. He, S., Wang, Q., He, J., Pu, H. et al., Proteomic analysis and comparison of the biopsy and autopsy specimen of human brain temporal lobe. Proteomics 2006, 6, 4987-4996.
10. Dumont, D., Noben, J. P., Verhaert, P., Stinissen, P., Robben, J., Gel-free analysis of the human brain proteome: Application of liquid chromatography and mass spectrometry on biopsy and autopsy samples. Proteomics 2006, 6, 4967-4977.
11. Wolters, D. A., Washburn, M. P., Yates, J. R. III, An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 2001, 73, 5683-5690.
12. Pan, S., Shi, M., Jin, J., Albin, R. L. et al., Proteomics identification of proteins in human cortex using multi-dimensional separations and MALDI tandem mass spectrometer. Mol. Cell. Proteomics 2007 6, 1818-1823.
13. Bizzarro, A., Marra, C., Acciarri, A., Valenza, A. et al., Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2005, 20, 254-261.
14. Papassotiropoulos, A., Bagli, M., Kurz, A., Kornhuber, J. et al., A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann. Neurol. 2000, 47, 399-403.
15. Julien, J. P., A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem. Cell Biol. 1995, 73, 593-597.
16. Kitsou, E., Pan, S.Zhang, J. P. Shi, M. et al., Identification of proteins in human substantia nigra. Proteomics Clin. Appl. 2008, 2, 776-782.
17. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., Del Tredici, K., Stages in the development of Parkinson's diseaserelated pathology. Cell Tissue Res. 2004, 318, 121-134.
18. Kosaka, K., Iseki, E., Dementia with Lewy bodies. Curr. Opin. Neurol. 1996, 9, 271-275.
19. Wakabayashi, K., Tanji, K., Mori, F., Takahashi, H., The LB in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007, 27, 494-506.
20. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A. et al., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24, 197-211.
21. Leverenz, J. B., Umar, I., Wang, Q., Montine, T. J. et al., Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol. 2007, 17, 139-145.
22. Braak, H., Braak, E., Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 1996, 165, 3-12.
23. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P., Lu, K. P., The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999, 399, 784-788.
24. Holzer, M., Gartner, U., Stobe, A., Hartig, W. et al., Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathol. (Berl.) 2002, 104, 471-481.
25. Ramakrishnan, P., Dickson, D. W., Davies, P., Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiol. Dis. 2003, 14, 251-264.
26. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J. et al., Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol. Aging 2006, 27, 918-925.
27. Butterfield, D. A., Abdul, H.M., Opii, W., Newman, S. F. et al., Pin1 in Alzheimer's disease. J. Neurochem. 2006, 98, 1697-1706.
28. Wang, Q., Woltjer, R. L., Cimino, P. J., Pan, C. et al., Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J. 2005, 19, 869-871.
29. Olah, J., Tokesi, N., Vincze, O., Horvath, I. et al., Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. FEBS Lett. 2006, 580, 5807-5814.
30. Sultana, R., Boyd-Kimball, D., Cai, J., Pierce, W. M. et al., Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 2007, 11, 153-164.
31. Glenner, G. G., Wong, C. W., Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120, 885-890.
32. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G. et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82, 4245-4249.
33. Atwood, C. S., Martins, R. N., Smith, M. A., Perry, G., Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 2002, 23, 1343-1350.
34. Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z. et al., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440, 528-534.
35. Liao, L., Cheng, D., Wang, J., Duong, D. M. et al., Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 2004, 279, 37061-37068.
36. Braak, H., Rub, U., Del Tredici, K., Cognitive decline correlates with neuropathological stage in Parkinson's disease. J. Neurol. Sci. 2006, 248, 255-258.
37. Shi, M., Jin, J., Wang, Y., Beyer, R. P. et al., Mortalin: A protein associated with progression of Parkinson disease? J. Neuropathol. Exp. Neurol. 2008, 67, 117-124.
38. Kaul, S. C., Deocaris, C. C., Wadhwa, R., Three faces of mortalin: A housekeeper, guardian and killer. Exp. Gerontol. 2007, 42, 263-274.
39. Jin, J., Hulette, C., Wang, Y., Zhang, T. et al., Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: Relevance to Parkinson disease. Mol. Cell. Proteomics 2006, 5, 1193-1204.
40. Baba, M., Nakajo, S., Tu, P. H., Tomita, T. et al., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152, 879-884.
41. Trojanowski, J. Q., Lee, V. M., Brain degeneration linked to "fatal attractions" of proteins in Alzheimer's disease and related disorders. J. Alzheimers Dis. 2001, 3, 117-119.
42. Skovronsky, D. M., Lee, V. M., Trojanowski, J. Q., Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 2006, 1, 151-170.
43. Woltjer, R. L., Cimino, P. J., Boutte, A. M., Schantz, A. M. et al., Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimer's disease. FASEB J. 2005, 19, 1923-1925.
44. Yang, W., Woltjer, R. L., Sokal, I., Pan, C. et al., Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. Am. J. Pathol. 2007, 171, 993-1002.
45. Winton, M. J., Joyce, S., Zhukareva, V., Practico, D. et al., Characterization of tau pathologies in gray and whitematter of Guam parkinsonism-dementia complex. Acta Neuropathol. (Berl.) 2006, 111, 401-412.
46. Sebeo, J., Hof, P. R., Perl, D. P., Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Acta Neuropathol. 2004, 107, 497-503.
47. Forman, M. S., Schmidt, M. L., Kasturi, S., Perl, D. P. et al., Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am. J. Pathol. 2002, 160, 1725-1731.
48. Yamazaki, M., Arai, Y., Baba, M., Iwatsubo, T. et al., Alphasynuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J. Neuropathol. Exp. Neurol. 2000, 59, 585-591.
49. Ehringer, H., Hornykiewicz, O., Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 1960, 38, 1236-1239.
50. Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B. et al., Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4, 3943-3952.
51. Abdi, F., Quinn, J. F., Jankovic, J., McIntosh, M. et al., Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 2006, 9, 293-348.
52. Schapira, A. H., Mann, V. M., Cooper, J. M., Krige, D. et al., Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 1992, 32, S116-S124.
53. Jenner, P., Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53, S26-36; discussion S36-S38.
54. McNaught, K. S., Jackson, T., JnoBaptiste, R., Kapustin, A., Olanow, C. W., Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 2006, 66, S37-S49.
55. McGeer, P. L., McGeer, E. G., Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 2004, 10, S3-S7.
56. Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D. et al., Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279, 13256-13264.
57. Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D. et al., Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 2006, 281, 10816-10824.
58. Fahn, S., Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 2003, 991, 1-14.
59. Albin, R. L., Young, A. B., Penney, J. B., The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12, 366-375.
60. Crossman, A. R., Neural mechanisms in disorders of movement. Comp. Biochem. Physiol. A 1989, 93, 141-149.
61. DeLong, M. R., Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13, 281-285.
62. Cohen, G., Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984, 5, 77-82.
63. Halliwell, B., Oxidative stress and neurodegeneration: Where are we now? J. Neurochem. 2006, 97, 1634-1658.
64. Damier, P., Hirsch, E. C., Agid, Y., Graybiel, A. M., The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122, 1437-1448.
65. Fearnley, J. M., Lees, A. J., Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991, 114, 2283-2301.
66. Pakkenberg, B., Moller, A., Gundersen, H. J., Mouritzen Dam, A., Pakkenberg, H., The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry 1991, 54, 30-33.
67. McGeer, P. L., Itagaki, S., Akiyama, H., McGeer, E. G., Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 1988, 24, 574-576.
68. McRitchie, D. A., Cartwright, H. R., Halliday, G. M., Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol. 1997, 144, 202-213.
69. German, D. C., Dubach, M., Askari, S., Speciale, S. G., Bowden, D. M., 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridineinduced parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? Neuroscience 1988, 24, 161-174.
70. Varastet, M., Riche, D., Maziere, M., Hantraye, P., Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 1994, 63, 47-56.
71. Waters, C. M., Hunt, S. P., Jenner, P., Marsden, C. D., An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the marmoset. Neuroscience 1987, 23, 1025-1039.
72. German, D. C., Nelson, E. L., Liang, C. L., Speciale, S. G. et al., The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 1996, 5, 299-312.
73. Rodriguez, M., Barroso-Chinea, P., Abdala, P., Obeso, J., Gonzalez-Hernandez, T., Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: Similarities with cell loss in parkinson's disease. Exp. Neurol. 2001, 169, 163-181.
74. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M. et al., Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3, 1301-1306.
75. Greene, J. G., Dingledine, R., Greenamyre, J. T., Gene expression profiling of rat midbrain dopamine neurons: Implications for selective vulnerability in parkinsonism. Neurobiol. Dis. 2005, 18, 19-31.
76. Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A. et al., Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 2005, 14, 1709-1725.
77. Link, A. J., Eng, J., Schieltz, D. M., Carmack, E. et al., Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 1999, 17, 676-682.
78. Alexa, A., Rahnenfuhrer, J., Lengauer, T., Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006, 22, 1600-1607.
79. Zougman, A., Pilch, B., Podtelejnikov, A., Kiehntopf, M. et al., Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res. 2008, 7, 386-399.
80. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O. et al., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256-259.
81. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E. et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276, 2045-2047.
82. Sossi, V., de la Fuente-Fernandez, R., Schulzer, M., Troiano, A. R. et al., Dopamine transporter relation to dopamine turnover in Parkinson's disease: A positron emission tomography study. Ann. Neurol. 2007, 62, 468-474.
83. Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D. et al., Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. USA 1999, 96, 15268-15273.
84. Kuhlenbaumer, G., Hannibal, M. C., Nelis, E., Schirmacher, A. et al., Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat. Genet. 2005, 37, 1044-1046.
85. Soreghan, B. A., Lu, B. W., Thomas, S. N., Duff, K. et al., Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimer's disease. J. Alzheimers Dis. 2005, 8, 227-241.
86. Pan, S., Zhu, D., Quinn, J. F., Peskind, E. R. et al., A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 2007, 7, 469-473.
87. Trojanowski, J. Q., Lee, V. M., The role of tau in Alzheimer's disease. Med. Clin. North Am. 2002, 86, 615-627.
88. Farrer, M. J., Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Genet. 2006, 7, 306-318.
89. Andersson, L., Porath, J., Isolation of phosphoproteins by immobilized metal (Fe3+) affinity chromatography. Anal. Biochem. 1986, 154, 250-254.
90. Villen, J., Beausoleil, S. A., Gerber, S. A., Gygi, S. P., Largescale phosphorylation analysis of mouse liver. Proc. Natl. Acad. Sci. USA 2007, 104, 1488-1493.
91. Zhang, Y., Wolf-Yadlin, A., Ross, P. L., Pappin, D. J. et al., Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 2005, 4, 1240-1250.
92. Rush, J., Moritz, A., Lee, K. A., Guo, A. et al., Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 2005, 23, 94-101.
93. Oda, Y., Nagasu, T., Chait, B. T., Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat. Biotechnol. 2001, 19, 379-382.
94. Steen, H., Mann, M., A new derivatization strategy for the analysis of phosphopeptides by precursor ion scanning in positive ion mode. J. Am. Soc. Mass Spectrom. 2002, 13, 996-1003.
95. Zhou, H., Watts, J. D., Aebersold, R., A systematic approach to the analysis of protein phosphorylation. Nat. Biotechnol. 2001, 19, 375-378.
96. Kang, T. H., Bae, K. H., Yu, M. J., Kim, W. K. et al., Phosphoproteomic analysis of neuronal cell death by glutamate-induced oxidative stress. Proteomics 2007, 7, 2624-2635.
97. Ishihama, Y., Wei, F. Y., Aoshima, K., Sato, T. et al., Enhancement of the efficiency of phosphoproteomic identification by removing phosphates after phosphopeptide enrichment. J. Proteome Res. 2007, 6, 1139-1144.
98. DeGiorgis, J. A., Jaffe, H., Moreira, J. E., Carlotti, C. G., Jr. et al., Phosphoproteomic analysis of synaptosomes from human cerebral cortex. J. Proteome Res. 2005, 4, 306-315.
99. Chi, A., Huttenhower, C., Geer, L. Y., Coon, J. J. et al., Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron transfer dissociation (ETD) mass spectrometry. Proc. Natl. Acad. Sci. USA 2007, 104, 2193-2198.
100. Mikesh, L.M., Ueberheide, B., Chi, A., Coon, J. J. et al., The utility of ETD mass spectrometry in proteomic analysis. Biochim. Biophys. Acta 2006, 1764, 1811-1822.
101. Zubarev, R. A., Electron-capture dissociation tandem mass spectrometry. Curr. Opin. Biotechnol. 2004, 15, 12-16.
102. Ross, C. A., Pickart, C. M., The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004, 14, 703-711.
103. Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K. et al., Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 2002, 277, 49071-49076.
104. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M. et al., Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 1993, 10, 1151-1160.
105. McKeith, I. G., Ince, P., Jaros, E. B., Fairbairn, A. et al., What are the relations between Lewy body disease and AD? J. Neural. Transm. Suppl. 1998, 54, 107-116.
106. Meller, R., Thompson, S. J., Lusardi, T. A., Ordonez, A. N. et al., Ubiquitin proteasome-mediated synaptic reorganization: A novel mechanism underlying rapid ischemic tolerance. J. Neurosci. 2008, 28, 50-59.
107. Pan, S., Wang, Y., Quinn, J. F., Peskind, E. R. et al., Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J. Proteome Res. 2006, 5, 2769-2779.
108. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y. et al., Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25, 302-305.
109. Fodero, L. R., Saez-Valero, J., Barquero, M. S., Marcos, A. et al., Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. J. Neurochem. 2001, 79, 1022-1026.
110. Botella-Lopez, A., Burgaya, F., Gavin, R., Garcia-Ayllon, M. S. et al., Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103, 5573-5578.
111. Barrachina, M., Maes, T., Buesa, C., Ferrer, I., Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 2006, 32, 505-516.
112. Butterfield, D. A., Proteomics: A new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 2004, 1000, 1-7.
113. Perluigi, M., Poon, H. F., Maragos, W., Pierce, W. M. et al., Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: A model of Huntington disease. Mol. Cell. Proteomics 2005, 4, 1849-1861.
114. Poon, H. F., Frasier, M., Shreve, N., Calabrese, V. et al., Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice - a model of familial Parkinson's disease. Neurobiol. Dis. 2005, 18, 492-498.
115. Aebersold, R., Constellations in a cellular universe. Nature 2003, 422, 115-116.
116. Pan, S., Zhang, H., Rush, J., Eng, J. et al., High throughput proteome screening for biomarker detection. Mol. Cell. Proteomics 2005, 4, 182-190.
117. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., Gygi, S. P., Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA 2003, 100, 6940-6945.
118. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B. et al., Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 2004, 3, 235-244.
119. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
120. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
121. Pan, S., Rush, J., Peskind, E. R., Galasko, D. et al., Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res. 2008, 8, 720-730.